Lunacalcipol

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameLunacalcipol
Drug Alias Name鲁那卡泊醇MT-2832CTA018 InjectionCTA018 CapsuleCTA018 Cream +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytochrome P450 24A1 inhibitorsVitamin D receptor agonists
TargetsCytochrome P450 24A1Vitamin D receptor
Therapy Area/IndicationsHyperparathyroidism, SecondaryPsoriasisRenal Insufficiency, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOpko Health Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOpko Health IncOpko Ip Holdings Ii Inc
Active IndicationsN/A
Inactive IndicationsHyperparathyroidism, SecondaryPsoriasisRenal Insufficiency, Chronic +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG